PDF(Pubmed)
Abstract：
UNASSIGNED: This study aimed to investigate whether the impaired ciliary length and aberrant ciliary ultrastructure marker, dynein axonemal intermediate chain 1 (DNAI1), are important pathological characteristics in nasal mucosa from patients with allergic rhinitis (AR).
UNASSIGNED: Biopsies were taken from the inferior turbinate (IT) of controls (n = 20) and patients with AR (n = 20). The ciliary length and the DNAI1 location patterns were assessed by using immunofluorescent staining. Three patterns of DNAI1 localization were defined using a semi-quantitative scoring system: normal (N), partial (P) and absence (A). Every individual section was assigned a score between 0 and 2 in each high-power field (5 fields per sample). The score of 0 = pattern N >70%; 1 = patterns N + P >70%; and 2 = pattern A ≥30%. The receiver operating characteristic (ROC) curve was used to evaluate the predicted value of DNAI1 score for AR.
UNASSIGNED: The ciliary length was reduced by 33.3% in patients with AR compared with controls (P < 0.0001). The higher DNAI1 score was found in the AR group, with a median (first and third quartile) of 0.9 (0.4 and 1.08), which was 0.1 (0 and 0.76) in the control group (P = 0.0071). The ROC of DNAI1 was calculated based on the area under the curve of 0.74 (P = 0.0094). The cutoff value of ROC was 0.5833, with a sensitivity and specificity of 70%.
UNASSIGNED: These results suggested that the shorter ciliary length and aberrant localization of DNAI1 are potentially important pathological characteristics of the allergic nasal mucosa. The aberrant localization of DNAI1 may provide a novel candidate target for clinical management of AR.
UNASSIGNED: Biopsies were taken from the inferior turbinate (IT) of controls (n = 20) and patients with AR (n = 20). The ciliary length and the DNAI1 location patterns were assessed by using immunofluorescent staining. Three patterns of DNAI1 localization were defined using a semi-quantitative scoring system: normal (N), partial (P) and absence (A). Every individual section was assigned a score between 0 and 2 in each high-power field (5 fields per sample). The score of 0 = pattern N >70%; 1 = patterns N + P >70%; and 2 = pattern A ≥30%. The receiver operating characteristic (ROC) curve was used to evaluate the predicted value of DNAI1 score for AR.
UNASSIGNED: The ciliary length was reduced by 33.3% in patients with AR compared with controls (P < 0.0001). The higher DNAI1 score was found in the AR group, with a median (first and third quartile) of 0.9 (0.4 and 1.08), which was 0.1 (0 and 0.76) in the control group (P = 0.0071). The ROC of DNAI1 was calculated based on the area under the curve of 0.74 (P = 0.0094). The cutoff value of ROC was 0.5833, with a sensitivity and specificity of 70%.
UNASSIGNED: These results suggested that the shorter ciliary length and aberrant localization of DNAI1 are potentially important pathological characteristics of the allergic nasal mucosa. The aberrant localization of DNAI1 may provide a novel candidate target for clinical management of AR.
摘要：
未经证实：本研究旨在调查纤毛长度受损和异常纤毛超微结构标记物，动力蛋白轴突中间链1（DNAI1），是变应性鼻炎(AR)患者鼻粘膜的重要病理特点。
未经证实：活检取自对照组（n=20）和AR患者（n=20）的下鼻甲（IT）。通过使用免疫荧光染色评估纤毛长度和DNAI1位置模式。使用半定量评分系统定义了DNAI1定位的三种模式：正常（N），部分(P)和缺失(A)。在每个高倍视野(每个样本5个视野)中,每个单独的切片被分配0和2之间的分数。评分0=模式N>70%;1=模式N+P>70%;2=模式A≥30%。使用受试者工作特征（ROC）曲线评估DNAI1评分对AR的预测值。
UNASSIGNED：与对照组相比，AR患者的纤毛长度减少了33.3％（P<0.0001）。AR组DNAI1评分越高,中位数（第一和第三四分位数）为0.9（0.4和1.08），对照组为0.1(0和0.76)(P=0.0071)。基于0.74的曲线下面积计算DNAI1的ROC(P=0.0094)。ROC的截断值为0.5833,灵敏度和特异度为70%。
UNASSIGNED：这些结果表明纤毛长度较短和DNAI1的异常定位是变应性鼻粘膜的潜在重要病理特征。DNAI1的异常定位可能为AR的临床管理提供新的候选靶标。
未经证实：活检取自对照组（n=20）和AR患者（n=20）的下鼻甲（IT）。通过使用免疫荧光染色评估纤毛长度和DNAI1位置模式。使用半定量评分系统定义了DNAI1定位的三种模式：正常（N），部分(P)和缺失(A)。在每个高倍视野(每个样本5个视野)中,每个单独的切片被分配0和2之间的分数。评分0=模式N>70%;1=模式N+P>70%;2=模式A≥30%。使用受试者工作特征（ROC）曲线评估DNAI1评分对AR的预测值。
UNASSIGNED：与对照组相比，AR患者的纤毛长度减少了33.3％（P<0.0001）。AR组DNAI1评分越高,中位数（第一和第三四分位数）为0.9（0.4和1.08），对照组为0.1(0和0.76)(P=0.0071)。基于0.74的曲线下面积计算DNAI1的ROC(P=0.0094)。ROC的截断值为0.5833,灵敏度和特异度为70%。
UNASSIGNED：这些结果表明纤毛长度较短和DNAI1的异常定位是变应性鼻粘膜的潜在重要病理特征。DNAI1的异常定位可能为AR的临床管理提供新的候选靶标。
